Shandong Sito Bio-technology Co Ltd (300583) - Total Liabilities

Latest as of September 2025: CN¥1.06 Billion CNY ≈ $155.82 Million USD

Based on the latest financial reports, Shandong Sito Bio-technology Co Ltd (300583) has total liabilities worth CN¥1.06 Billion CNY (≈ $155.82 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Shandong Sito Bio-technology Co Ltd - Total Liabilities Trend (2012–2024)

This chart illustrates how Shandong Sito Bio-technology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 300583 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Shandong Sito Bio-technology Co Ltd Competitors by Total Liabilities

The table below lists competitors of Shandong Sito Bio-technology Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
Fortune Ng Fung Food Hebei Co Ltd
SHG:600965
China CN¥462.39 Million
Firm Capital Mortgage Invest Corp
TO:FC
Canada CA$133.58 Million
Materialise NV
NASDAQ:MTLS
USA $162.93 Million
Jiangsu Xinning Modern Logist
SHE:300013
China CN¥354.76 Million
Peijia Medical Limited
F:4WO
Germany €798.71 Million
Silence Therapeutics PLC
NASDAQ:SLN
USA $72.73 Million
Citizens Financial Services Inc. Common Stock
NASDAQ:CZFS
USA $2.68 Billion

Liability Composition Analysis (2012–2024)

This chart breaks down Shandong Sito Bio-technology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Shandong Sito Bio-technology Co Ltd worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.21 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.60 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.37 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Shandong Sito Bio-technology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Shandong Sito Bio-technology Co Ltd (2012–2024)

The table below shows the annual total liabilities of Shandong Sito Bio-technology Co Ltd from 2012 to 2024.

Year Total Liabilities Change
2024-12-31 CN¥1.14 Billion
≈ $167.06 Million
-2.82%
2023-12-31 CN¥1.17 Billion
≈ $171.91 Million
-4.04%
2022-12-31 CN¥1.22 Billion
≈ $179.15 Million
-1.09%
2021-12-31 CN¥1.24 Billion
≈ $181.11 Million
+7.63%
2020-12-31 CN¥1.15 Billion
≈ $168.27 Million
+4.49%
2019-12-31 CN¥1.10 Billion
≈ $161.04 Million
+50.21%
2018-12-31 CN¥732.63 Million
≈ $107.21 Million
+130.81%
2017-12-31 CN¥317.42 Million
≈ $46.45 Million
-4.74%
2016-12-31 CN¥333.22 Million
≈ $48.76 Million
+0.48%
2015-12-31 CN¥331.62 Million
≈ $48.53 Million
+53.30%
2014-12-31 CN¥216.31 Million
≈ $31.65 Million
+93.44%
2013-12-31 CN¥111.83 Million
≈ $16.36 Million
+306.45%
2012-12-31 CN¥27.51 Million
≈ $4.03 Million
--

About Shandong Sito Bio-technology Co Ltd

SHE:300583 China Biotechnology
Market Cap
$319.51 Million
CN¥2.18 Billion CNY
Market Cap Rank
#14617 Global
#4370 in China
Share Price
CN¥11.51
Change (1 day)
-1.79%
52-Week Range
CN¥11.51 - CN¥19.15
All Time High
CN¥50.68
About

Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, ethylene deltenone, 16ß and 16a me… Read more